艾美捷科技代理Prolume品牌。

Prolume Ltd. 由 Bruce Bryan 博士及其团队创立，专注于生物发光技术的研究与开发。公司通过其子公司 NanoLight® Technologies 提供广泛的生物发光试剂和报告系统，服务于制药、农业化学品和研究产品行业。Prolume的3种来自海洋刺胞动物（Renilla mulleri、Renilla reniformis和Ptilosarcus）的绿色荧光蛋白（GFP）在本质上比市场上任何其他GFP都更亮，包括著名的Aequorea GFP中最亮的变体。Prolume的GFP在多种领域具有许多潜在用途，如药物发现和生物医学研究；高通量筛选（HTS）；荧光激活细胞分选（FACS）；转基因报告细胞、动物和植物中的基因表达；环境和过程监测；以及许多蛋白质组学应用，包括蛋白质生物芯片，以及使用FRET或BRET动态监测蛋白质相互作用。Prolume 目前正在开发一种具有专利权的桡足类发光酶（Gaussia princeps），这种酶非常明亮、体积小且生化性能强大。Prolume 还大量合成 Coelenterazine，这是光蛋白 Aequorin 和许多发光酶（包括 Renilla reniformis 和 Gaussia 的酶）天然使用的荧光素。

Nanoprobes公司专业生产免疫金标记和免疫测定试验产品。其独特的金标技术使用化学交联的金属和纳米颗粒团簇作为标记。与胶体金颗粒静电吸附在抗体和蛋白质上的传统免疫金探针不同，本公司的金标是与生物分子在特定位点交联的不带电荷的分子。这使我们的探针具有胶体金不具备的范围和灵活性。我们的标记可以附着在任何带有反应基的分子上– 蛋白质、多肽、寡核苷酸、小分子和脂类 - 以检测和定位这些分子。其他标记可以与我们的金标共同使用，我们独特的荧光纳米金探针在一个探针中结合了纳米金（nanogold®）和荧光素，用于荧光和电镜两种技术共同进行样品成像。

Nanoprobes was founded in 1990 by Dr. James F. Hainfeld, along with a group of scientists who were also alumni of Brookhaven National Laboratory. The independent research facility they formed has allowed Dr. Hainfeld and his colleagues the freedom to pursue some of the greatest challenges in research: seeking cures for cancer and other diseases.

While part of the funding for these endeavors has come from research grants, another source had to be found, as the scientific community faces ever-increasing government cutbacks. To this end, Nanoprobes began to offer many of the nanoparticle technologies developed by its members for use in other scientists' research.

Nanoprobes公司主要产品：

AuroVist™ 15 nm & 1.9 nm X-ray Contrast Agent

Conjugates

Enhancement / Developers

EnzMet™ ultra-sensitive

Gold Nanomaterials: Functionalized Nanoparticles

Gold Nanoparticle Reagents

Histadine (His) Tag Labeling

Recombinant Protein Detection

FerroMag™ Magnetic nanoparticles

Negative Stains for EM

Xray Contrast Agents

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com

Dendritics公司主要关注人类树突状细胞，希望找到能够促使CD34+造血前体细胞转化为树突状细胞（在GM-CSF和TNF-alpha存在的情况下）的细胞因子。在1992-2005年间，大量的研究使得研究者对人类树突状细胞的产生、细胞通路、C-type凝集素受体的功能及Toll-like受体的活性有了更深的理解。

DENDRITICS was started in 2005 by former members of SCHERING PLOUGH Laboratory for Immunological Research (LIR) in Dardilly, France. From their long experience at LIR, the team members of DENDRITICS have gathered complementary scientific and technological knowledge in different areas of immunology. The initial focus of LIR was in the biology of B lymphocytes, elaboration of human monoclonal antibodies, and in cytokine discovery (IL-3, IL-4, IL-7, IL-10, IL-17, GM-CSF) together with our colleagues of DNAX Research Institute in Palo Alto, California.

Our interest in cytokines led to the finding that human dendritic cells (DCs) could be generated in vitro from CD34+ hematopoietic progenitors cultured in the presence of GM-CSF and TNF-alpha.

The period from 1992 to 2005 saw the specialization of LIR in DC biology and was fuelled by a large-scale effort to discover and study the function of genes specifically expressed by these cells. This program led to a number of findings that contributed in particular to understanding the heterogeneity of DCs, the pathways regulating DC migration, the function of C-type lectin receptors in DCs and the activity of Toll-like receptors in DCs. Many novel genes were discovered through screening of cDNA libraries or through monoclonal antibodies raised against DCs.

更多详情请联系 

艾美捷科技有限公司

全国服务热线：400-6800-868

邮箱：sales@amyjet.com

网站：www.amyjet.com